HER2 mutation generally accompanied a higher TMB than HER2 wild-type in various tumors, except kidney renal papillary cell carcinoma, lung squamous cell carcinoma (LUSC), and uterine carcinosarcoma (UCS) (Supplementary Figure S2). Here, ERBB2 is linked to squamous cell lung carcinoma.